1.  Home
  2. Whitepapers
  3. Bioorthogonal Photocatalytic Reactions of Flavins Converting PtIV Substrates into PtII Anticancer Drugs; Photoluminescence and Transient Absorption Data

Bioorthogonal Photocatalytic Reactions of Flavins Converting PtIV Substrates into PtII Anticancer Drugs; Photoluminescence and Transient Absorption Data

Download Whitepaper

Bioorthogonal Photocatalytic Reactions of Flavins Converting PtIV Substrates into PtII Anticancer Drugs; Photoluminescence and Transient Absorption Data

Download Whitepaper
  • Author: Ian N. Stanton, Ph. D.
The ideal anticancer drug would be one that is effective at killing rapidly producing cells, is targeted directly to the tumour location, and is non-toxic until it reaches the diseased area. Platinum-II (PtII) based chemotherapy drugs have been life changing for many, with the most common drug, Cisplatin, providing treatment and cures for cancerous diseases in the bladder, breast, cervix, lung, ovaries, and head and neck, to name a few. In the active drug form, PtII binds to DNA which interferes with cellular replication, killing the rapidly proliferating cancerous cells. However, PtII is also toxic to healthy cells, causing severe side effects, especially in those with pre-existing kidney issues.

Download Whitepaper Now